Mankind Pharma delivered a strong finish to the fiscal year, reporting an 11.8% year-on-year revenue increase in Q4 FY26, reaching INR 3,443 crore. The company’s adjusted EBITDA margin expanded to 27.1%, fueled by double-digit growth in its domestic business and specialty chronic portfolio. Despite geo-political headwinds affecting international sales, the company remains focused on strengthening its core pillars of steady base business, specialty chronic growth, and consumer healthcare expansion.
Financial Performance Highlights
For the quarter ended March 31, 2026, Mankind Pharma demonstrated robust financial health. The company achieved INR 3,443 crore in revenue from operations, an 11.8% YoY growth. Profitability metrics also saw significant improvement, with an adjusted EBITDA margin of 27.1%, marking a 400 bps increase over the previous year. Diluted EPS stood at INR 13.4, representing a 30.3% YoY rise.
For the full FY26, the company reported total revenue of INR 14,278 crore, up 17.0% from the previous fiscal year, with an adjusted EBITDA of INR 3,629 crore.
Domestic and Specialty Growth
The domestic business remains the primary growth engine, growing by 13% YoY. This performance was anchored by strong results in chronic therapies, including a 14.7% growth in Cardiac and 11.6% in Anti-diabetes products. The company successfully increased its chronic market share by 120 bps to approximately 40%. Additionally, the specialty business under the BSV portfolio contributed significantly, with key brands like Foligraf and Ossopan reporting substantial growth of 52% and 72%, respectively.
Consumer Healthcare and Future Outlook
The Consumer Healthcare business saw a 20% YoY growth in Q4, driven by the strong market performance of brands such as Manforce, Prega News, Gasofast, and Nimulid. The company has successfully expanded its footprint in E-commerce and Modern Trade channels, with their collective share rising to 13% in FY26 compared to 9% in FY25. Looking ahead, Mankind Pharma continues to leverage its network of 18,500+ field professionals and 32 manufacturing facilities to advance its four-pillar strategy: steady base business, fast-growing specialty chronic, high-potential OTC products, and the super-specialty BSV portfolio.
Source: BSE
